share_log

Bristol-Myers Squibb | CORRESP: CORRESP

Bristol-Myers Squibb | CORRESP: CORRESP

施贵宝 | CORRESP：信函
SEC announcement ·  02/16 16:33
Moomoo AI 已提取核心信息
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
Bristol-Myers Squibb Company (BMS) has responded to a comment letter from the U.S. Securities and Exchange Commission (SEC) regarding its tender offer statement for RayzeBio, Inc., initially filed on January 25, 2024. The SEC's letter, dated February 14, 2024, raised concerns about BMS's financing plans, the conditions of the offer, and the acceptance of tenders from shareholders in compliance with jurisdictional laws. BMS, along with its wholly owned subsidiary Rudolph Merger Sub Inc., has filed an amendment to the tender offer statement, addressing the SEC's comments and confirming their intention to comply with Commission rules and regulations. The amendment includes revised disclosures about the source and amount of funds, the conditions to the offer, and the acceptance of tenders from shareholders. BMS has assured the SEC that it will promptly inform RayzeBio stockholders of any developments that may affect the satisfaction of offer conditions.
百时美施贵宝公司（BMS）回应了美国证券交易委员会（SEC）关于其最初于2024年1月25日提交的RayzeBio, Inc.的要约声明的评论信。美国证券交易委员会于2024年2月14日发出的信函对BMS的融资计划、要约条件以及根据司法管辖法接受股东的投标表示担忧。BMS及其全资子公司Rudolph Merger Sub Inc. 已对要约声明提交了修正案，回应了美国证券交易委员会的评论并确认了他们遵守委员会规章制度的意向。该修正案包括对资金来源和金额、要约条件以及股东接受投标的修订披露。BMS已向美国证券交易委员会保证，它将立即向RayzeBio股东通报任何可能影响报价条件满意度的事态发展。
百时美施贵宝公司（BMS）回应了美国证券交易委员会（SEC）关于其最初于2024年1月25日提交的RayzeBio, Inc.的要约声明的评论信。美国证券交易委员会于2024年2月14日发出的信函对BMS的融资计划、要约条件以及根据司法管辖法接受股东的投标表示担忧。BMS及其全资子公司Rudolph Merger Sub Inc. 已对要约声明提交了修正案，回应了美国证券交易委员会的评论并确认了他们遵守委员会规章制度的意向。该修正案包括对资金来源和金额、要约条件以及股东接受投标的修订披露。BMS已向美国证券交易委员会保证，它将立即向RayzeBio股东通报任何可能影响报价条件满意度的事态发展。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息